+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Point-of-Care Diagnostics Market for Infectious Diseases by Indication, Type of Technology and Geography: Industry Trends and Global Forecasts, 2020-2030

  • ID: 5215163
  • Report
  • September 2020
  • Region: Global
  • 235 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 3M Health Care
  • BIOgenetiX
  • efyian
  • KAINOS Laboratories
  • OpGen
  • Sepsitron
  • MORE

Overview

According to the World Health Organization (WHO), the big three infectious diseases, namely human immunodeficiency virus / acquired immunodeficiency syndrome (HIV / AIDS), malaria and tuberculosis (TB), are reported to be the cause of approximately 2.5 million annual fatalities worldwide. Moreover, the pathogens responsible for causing these diseases are known to undergo selective mutations, which make them resistant to commonly used antibiotics. This impedes the effective treatment of the aforementioned clinical conditions. Since the pathophysiology of such diseases is known to evolve with time, better diagnostic tools with high sensitivity and specificity are required for timely diagnosis and better treatment related decision-making. For diseases of bacterial origin, diagnosis is based on culturing the pathogen; this is considered the current gold standard. Although these methods are highly specific, they are time consuming, requiring three to five days for detecting the responsible pathogen. On the other hand, in case of viral infections, molecular diagnostic platforms, such as next generation sequencing and real-time polymerase chain reactions, are typically used. However, these molecular level analytical techniques are expensive, complicated, and generally inaccessible in resource-limited settings.

Given the aforementioned challenges, the medical industry is consistently engaged in efforts to innovate in assay formats, developing better biosensors, and bioanalytical platforms to expedite the diagnosis process. The concept of point-of-care diagnostics, or rapid diagnostics, has become even more popular with the novel coronavirus outbreak. Unlike the traditional laboratory-based tests, the results of a point-of-care test can be made available instantaneously (as fast as 5 minutes). This facilitates faster diagnosis and prompt decision making with respect to treatment, thereby, enabling the containment of infectious diseases at an early stage of transmission and preventing outbreaks. Additionally, point-of-care diagnostics have shown to reduce the reliance on presumptive treatment, thereby, helping curb the inappropriate use of antibiotics. Till date, point-of-care diagnostics are widely used for the diagnosis of diseases, such as chikungunya, COVID-19, dengue, hepatitis, malaria, pneumonia, and tuberculosis. In future, we expect such tests / assays to dominate the in vitro diagnostics market.

Scope of the Report

The ‘Point-of-Care Diagnostics Market for Infectious Diseases, 2020-2025’ report features an extensive study on point-of-care diagnostics that are either commercialized or are under development for diagnosis of different types of infections. In addition, it features an elaborate discussion on the likely future opportunity associated with such tools, over the next five years.

Amongst other elements, the report includes:

  • A detailed review of the overall landscape of point-of-care diagnostics for COVID-19, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), type of sample (blood, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed review of the overall landscape of Point-of-Care Diagnostics for tropical diseases, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indication (chikungunya, dengue, Ebola, malaria, and zika), type of sample (blood, sputum, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed review of the overall landscape of point-of-care diagnostics for respiratory infections, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indication (influenza, pneumonia, and tuberculosis), type of sample (blood, cerebrospinal fluid, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed review of the overall landscape of point-of-care diagnostics for HIV/AIDS and hepatitis, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indication (hepatitis A, hepatitis B, hepatitis C, and HIV/AIDS), type of sample (blood, feces, oral fluid, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed study of the overall landscape of point-of-care diagnostics for infectious diseases, featuring analyses based on a number of relevant parameters, such as type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indication (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes).
  • An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between January 2018 and July 2020, covering distribution and supply agreements, product development and commercialization agreements, commercialization agreements, mergers and acquisitions, product development and manufacturing agreements, research and development agreements, and product / technology integration agreements.
  • A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2018, and offering a means for other industry stakeholders to identify potential acquisition targets.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities. Based on various parameters, such as number of available / under development products, average price of point-of-care tests and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2020-2025. The report also features the likely distribution of the current and forecasted opportunity across [A] target disease indications (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), [B] type of technology (lateral flow, molecular diagnostics, fluorescence immunoassay, solid phase, and others), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Reuven Duer, Founder and CEO, Proactive Diagnostics
  • Giffin Daughtridge, CEO, UrSure
  • Abhinav Thakur, Managing Director, Accurex Biomedical
  • Gerrit Van Roekel, Director of Business Development, Hemex Health
  • Sofiane Bennacer, Business Development Manager, Credo Diagnostics Biomedical

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the prevalent trends within the point-of-care diagnostics market?
  • What are the key technologies being used in point-of-care diagnostics?
  • Who are the leading developers of point-of-care diagnostics for COVID-19?
  • Who are the leading developers of point-of-care diagnostics for tropical diseases (chikungunya, dengue, Ebola, malaria, and Zika) and respiratory infections (influenza, pneumonia, and tuberculosis)?
  • Who are the leading developers of point-of-care diagnostics for HIV/AIDS and hepatitis?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • How is the current and future market opportunity likely to be distributed across key market segments and geographical regions?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M Health Care
  • BIOgenetiX
  • efyian
  • KAINOS Laboratories
  • OpGen
  • Sepsitron
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Point-of-Care Diagnostics (POCDs)
3.2.1. Characteristics of an Ideal Point-of-Care Diagnostic
3.2.2. Technologies Used in Point-of-Care Diagnostics of Infectious Diseases
3.3. Challenges Associated with Point-of-Care Diagnostics
3.4. Future Perspectives

4. CURRENT MARKET LANDSCAPE (FOCUS ON COVID-19)
4.1. Chapter Overview
4.2. Point-of-Care Diagnostics for COVID-19: List of Products
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Product
4.2.3. Analysis by Type of Technology
4.2.4. Analysis by Type of Sample
4.2.5. Analysis by Sensitivity Range
4.2.6. Analysis by Specificity Range
4.2.7. Analysis by Turnaround Time
4.3. Point-of-Care Diagnostics for COVID-19: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size and Geographical Location
4.3.3. Leading Developers: Analysis by Number of Products
4.3.4. World Map Representation: Analysis by Regional Activity

5. CURRENT MARKET LANDSCAPE (FOCUS ON TROPICAL DISEASES)
5.1. Chapter Overview
5.2. Point-of-Care Diagnostics for Tropical Diseases: List of Products
5.2.1. Analysis by Status of Development
5.2.2. Analysis by Type of Product
5.2.3. Analysis by Type of Technology
5.2.4. Analysis by Target Disease Indication
5.2.5. Analysis by Type of Sample
5.2.6. Analysis by Sensitivity Range
5.2.7. Analysis by Specificity Range
5.2.8. Analysis by Turnaround Time
5.3. Point-of-Care Diagnostics for Tropical Diseases: List of Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size and Geographical Location
5.3.3. Leading Developers: Analysis by Number of Products
5.3.4. World Map Representation: Analysis by Regional Activity

6. CURRENT MARKET LANDSCAPE (FOCUS ON RESPIRATORY INFECTIONS)
6.1. Chapter Overview
6.2. Point-of-Care Diagnostics for Respiratory Infections: List of Products
6.2.1. Analysis by Status of Development
6.2.2. Analysis by Type of Product
6.2.3. Analysis by Type of Technology
6.2.4. Analysis by Target Disease Indication
6.2.5. Analysis by Type of Sample
6.2.6. Analysis by Sensitivity Range
6.2.7. Analysis by Specificity Range
6.2.8. Analysis by Turnaround Time
6.3. Point-of-Care Diagnostics for Respiratory Infections: List of Developers
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size and Geographical Location
6.3.3. Leading Developers: Analysis by Number of Products
6.3.4. World Map Representation: Analysis by Regional Activity

7. CURRENT MARKET LANDSCAPE (FOCUS ON HIV/AIDS AND HEPATITIS)
7.1. Chapter Overview
7.2. Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Products
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Type of Technology
7.2.4. Analysis by Target Disease Indication
7.2.5. Analysis by Type of Sample
7.2.6. Analysis by Sensitivity Range
7.2.7. Analysis by Specificity Range
7.2.8. Analysis by Turnaround Time
7.3. Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size and Geographical Location
7.3.3. Leading Developers: Analysis by Number of Products
7.3.4. World Map Representation: Analysis by Regional Activity

8. OVERALL MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Analysis by Type of Technology
8.3. Analysis by Target Disease Indication
8.4. Analysis by Sensitivity Range
8.5. Analysis by Specificity Range
8.6. Analysis by Turnaround Time

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Point-of-Care Diagnostics for Infectious Diseases: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Product
9.3.4. Analysis by Target Disease Indication
9.3.5. Analysis by Year and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Analysis
9.3.8. Intercontinental and Intracontinental Agreements

10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Scoring Criteria and Key Assumptions
10.4. Potential Strategic Acquisition Targets in North America
10.5. Potential Strategic Acquisition Targets in Europe
10.6. Potential Strategic Acquisition Targets in Asia-Pacific
10.7. Potential Strategic Acquisition Targets in Latin America
10.8. Potential Strategic Acquisition Targets in Middle East, North Africa, and Rest of the World
10.9. Concluding Remarks

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020-2025
11.4. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Target Disease Indication
11.4.1. Point-of-Care Diagnostics Market for COVID-19, 2020-2025
11.4.2. Point-of-Care Diagnostics Market for Chikungunya, 2020-2025
11.4.3. Point-of-Care Diagnostics Market for Dengue, 2020-2025
11.4.4. Point-of-Care Diagnostics Market for Ebola, 2020-2025
11.4.5. Point-of-Care Diagnostics Market for Hepatitis, 2020-2025
11.4.6. Point-of-Care Diagnostics Market for HIV/AIDS, 2020-2025
11.4.7. Point-of-Care Diagnostics Market for Influenza, 2020-2025
11.4.8. Point-of-Care Diagnostics Market for Malaria, 2020-2025
11.4.9. Point-of-Care Diagnostics Market for Pneumonia, 2020-2025
11.4.10. Point-of-Care Diagnostics Market for Tuberculosis, 2020-2025
11.4.11. Point-of-Care Diagnostics Market for Zika, 2020-2025
11.5. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Type of Technology
11.5.1. Point-of-Care Diagnostics for Infectious Diseases Market for Lateral Flow Assay, 2020-2025
11.5.2. Point-of-Care Diagnostics for Infectious Diseases Market for Molecular Diagnostics, 2020-2025
11.5.3. Point-of-Care Diagnostics for Infectious Diseases Market for Fluorescence Immunoassay, 2020-2025
11.5.4. Point-of-Care Diagnostics for Infectious Diseases Market for Solid Phase Assay, 2020-2025
11.5.5. Point-of-Care Diagnostics for Infectious Diseases Market for Other Technologies, 2020-2025
11.6. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Geography
11.6.1. Point-of-Care Diagnostics for Infectious Diseases Market in the US, 2020-2025
11.6.2. Point-of-Care Diagnostics for Infectious Diseases Market in Canada, 2020-2025
11.6.3. Point-of-Care Diagnostics for Infectious Diseases Market in the UK, 2020-2025
11.6.4. Point-of-Care Diagnostics for Infectious Diseases Market in Germany, 2020-2025
11.6.5. Point-of-Care Diagnostics for Infectious Diseases Market in Spain, 2020-2025
11.6.6. Point-of-Care Diagnostics for Infectious Diseases Market in France, 2020-2025
11.6.7. Point-of-Care Diagnostics for Infectious Diseases Market in Italy, 2020-2025
11.6.8. Point-of-Care Diagnostics for Infectious Diseases Market in China, 2020-2025
11.6.9. Point-of-Care Diagnostics for Infectious Diseases Market in India, 2020-2025
11.6.10. Point-of-Care Diagnostics for Infectious Diseases Market in Japan, 2020-2025
11.6.11. Point-of-Care Diagnostics for Infectious Diseases Market in Australia, 2020-2025
11.6.12. Point-of-Care Diagnostics for Infectious Diseases Market in Brazil, 2020-2025
11.6.13. Point-of-Care Diagnostics for Infectious Diseases Market in Argentina, 2020-2025
11.6.14. Point-of-Care Diagnostics for Infectious Diseases Market in Saudi Arabia, 2020-2025
11.6.15. Point-of-Care Diagnostics for Infectious Diseases Market in UAE, 2020-2025
11.6.16. Point-of-Care Diagnostics for Infectious Diseases Market in Egypt, 2020-2025
11.6.17. Point-of-Care Diagnostics for Infectious Diseases Market in South Africa, 2020-2025

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Proactive Diagnostics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Reuven Duer, Founder and Chief Executive Officer
12.3. UrSure
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Giffin Daughtridge, Chief Executive Officer
12.4. Accurex Biomedical
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Abhinav Thakur, Managing Director
12.5. Hemex Health
12.5.1. Company Snapshot
12.5.2. Interview Transcript: Gerrit Van Roekel, Director of Business Development
12.6. Credo Diagnostics Biomedical
12.6.1. Company Snapshot
12.6.2. Interview Transcript: Sofiane Bennacer, Business Development Manager

13. CONCLUDING REMARKS
 
14. APPENDIX 1: TABULATED DATA

Note: Product cover images may vary from those shown
  • 3M Health Care
  • A. Menarini Diagnostics
  • AAZ-LMB
  • Abacus Diagnostica
  • Abingdon Health
  • Abionic
  • Accel Diagnostics
  • Access Bio
  • AccuBioTech
  • Accurex Biomedical
  • Achira Labs
  • ACON Laboratories
  • Acro Biotech
  • Actionmed Medical Equipment Trading
  • ADS Biotec
  • ADVAITE
  • Advy Chemical
  • AgPlus Diagnostics
  • Aidian
  • AIL Dixon Technologies
  • AKO MED
  • Akonni Biosystems
  • ALAB
  • Alere
  • AlphaSIP Laboratories
  • ALUXBIO
  • American Bio Medica
  • American Leprosy Missions
  • American Screening
  • AMS UK
  • Anamol Laboratories
  • Anhui DeepBlue Medical Technology
  • Antagen Pharmaceuticals
  • Anteo Diagnostics
  • ApolloDx
  • Aquila Diagnostic Systems
  • Arbor Vita
  • ArcDia International
  • ARKRAY
  • ARKRAY Healthcare
  • Artron Laboratories
  • Asan Pharmaceutical
  • Ativa Medical
  • Atlas Link
  • Atlas Medical
  • Atomo Diagnostics
  • Augurix
  • Autobio Diagnostics
  • Avacta
  • Aviana Molecular Technologies
  • Axxin
  • Aytu BioScience
  • BBI Solutions
  • Becton, Dickinson
  • Bedford Biotech Nigeria
  • Beijing Hotgen Biotech
  • Beijing Kewei Clinical Diagnostic Reagent
  • Beijing Wantai Biological Pharmacy
  • BGI Group
  • Bhat Bio-tech India
  • BHR Pharmaceuticals
  • Biko
  • binx health
  • BioFab
  • BioFire Diagnostics
  • Biofootprints Healthcare
  • Biogate Laboratories
  • BIOgenetiX
  • Biolidics
  • bioLytical Laboratories
  • Bio-Manguinhos
  • Biomedical Advanced Research and Development Authority (BARDA)
  • BioMedomics
  • Biomeme
  • bioMérieux
  • Bionor
  • Biopanda Reagents
  • BioPorto Diagnostics
  • Bio-Rad Laboratories
  • Biosensia
  • Biosensorix
  • BioSpeedia
  • BioSure (UK)
  • biosurfit
  • Biosynex
  • Biotec Laboratories
  • Biozek medical
  • BluSense Diagnostics
  • Boditech Med
  • Bosch Healthcare Solutions
  • Brevitest Technologies
  • Bright Machines
  • Broad Institute
  • BTNX
  • Bundi International Diagnostics
  • Calypte Biomedical
  • Calyx Biotech
  • Canon Medical Systems
  • Carpegen
  • Cascade Biosystems
  • Cavidi
  • Cellex
  • Cellmic
  • Cepheid
  • CerTest Biotec
  • Chaim Sheba Medical Center
  • Checkable Medical
  • Chembio Diagnostic Systems
  • Chester County Health Department
  • CIGA Healthcare
  • CK Life Sciences
  • Clinton Health Access Initiative
  • Concepta
  • Confirm BioSciences
  • Corgenix Medical
  • Coris BioConcept
  • Creative Diagnostics
  • Credo Diagnostics Biomedical
  • CTK Biotech
  • Cue Health
  • Curetis
  • Curiosity Diagnostics
  • Cyient
  • Cypress Diagnostics
  • Cytiva
  • Datametrex AI
  • DCL Laboratory Products
  • DCN Diagnostics
  • Denka
  • Denka Seiken
  • Diagnostic Automation / Cortez Diagnostics
  • Diagnostics for the Real World (DRW)
  • DIALAB
  • DiaSorin
  • DiscoveryDX
  • DNA Electronics
  • Dolomite Microfluidics
  • Dynamiker Biotechnology (Tianjin)
  • E25Bio
  • Ebram Produtos Laboratoriais
  • ECO Diagnóstica
  • efyian
  • Eiken Chemical
  • Elabscience
  • Elena Diagnostic
  • ELG Medical
  • Ellume
  • EMPE Diagnostics
  • Era Biology
  • Eurobio Scientific
  • Evotech-Mirai Genomics (EMG)
  • Exhalation Medical Technology
  • EY Laboratories
  • FastSense Diagnostics
  • Fio
  • First Diagnostic
  • Firstep Bioresearch
  • Fluxergy
  • Focus Diagnostics
  • Foundation for Innovative New Diagnostics (FIND)
  • Frontage Laboratories
  • Frontida BioPharm
  • Fujirebio
  • Future HorizonS Scientific
  • Fyodor Biotechnologies
  • GaDia
  • GenBody
  • genedrive
  • GenePOC
  • Genesis Diagnostics
  • GenMark Diagnostics
  • GenPrime
  • GENSPEED Biotech
  • GeTein BioMedical
  • Ginolis
  • Glenbio
  • GoDx
  • Guangzhou Wondfo Biotech
  • Hangzhou AllTest Biotech
  • Hangzhou Biotest Biotech
  • Hangzhou Bosure Biotech
  • Hangzhou Genesis Biodetection & Biocontrol
  • Hangzhou Laihe Biotech
  • Hangzhou Testsea Biotechnology
  • Harvard University
  • HBI
  • Healgen Scientific
  • Hebei Times Medical Technology
  • Helix2
  • Hema Diagnostic Systems
  • Hemex Health
  • Henry Schein
  • HiberGene Diagnostics
  • HIGHTOP Biotech
  • Human Gesellschaft für Biochemica und Diagnostica
  • Humasis
  • iAssay
  • Ibn Rushd Medical & Scientific Equipment
  • ICT Diagnostics
  • Immunoshop
  • Immunostics
  • InBios International
  • Indian Council of Medical Research
  • InSilixa
  • Instadiagnostics
  • Instant NanoBiosensors
  • Institut Pasteur de Dakar
  • Intec Products
  • Integrated DNA Technologies
  • Interlab INTERAUTOMATIKA
  • Invenio Medical
  • J&G Biotech
  • J. Mitra
  • JAJ International
  • Jiangsu Dablood Pharmaceutical
  • JOYSBIO (Tianjin) Biotechnology
  • KAINOS Laboratories
  • Kephera Diagnostics
  • Kin Diagnostics
  • Köroğlu Medical Devices
  • Lab Care Diagnostics
  • Lab21
  • Labmaster
  • Labsystems Diagnostics
  • LamdaGen
  • Leaflife Technology
  • LifeSign
  • Liming Bio-Products
  • LT LABS
  • Luminex
  • Luminostics
  • LumiraDx
  • Lumos Diagnostics
  • Maccura Biotechnology
  • Mass General Brigham
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • Maternova
  • MBio Diagnostics
  • MBiolog Diagnósticos
  • McKesson Medical-Surgical
  • Medcaptain Medical Technology
  • Medical Communications Associates
  • Medical Innovation Ventures
  • MedicalSystem Biotechnology
  • Mediclone Biotech
  • Medimprint
  • MEDISENSOR
  • MedMira
  • Medusa19
  • Menarini Silicon Biosystems
  • Menssana Research
  • Meridian Bioscience
  • Meril Life Sciences
  • Mesa Biotech
  • MH Medical
  • MicrosensDx
  • Mobidiag
  • Mobile Assay
  • Mokobio Biotechnology
  • Molbio Diagnostics
  • Mologic
  • MONDIALAB
  • Moroccan Foundation for Advanced Science Innovation & Research (MAScIR)
  • Mossman Associates
  • MP Biomedicals
  • Mylan
  • nal von minden
  • Nanobiosym
  • Nano-Ditech
  • NanoDx
  • NanoEnTek
  • Nanōmix
  • National Institute of Infectious Diseases
  • Nectar Lifesciences
  • NextGen Invitro Diagnostics (NGIVD)
  • Nexus Dx
  • NG Biotech
  • Noul
  • NowAware
  • NOWDiagnostics
  • NTBIO Diagnostics
  • Nulife Care
  • Oasis Diagnostics
  • OMC Healthcare
  • Omega Diagnostics
  • One Milo
  • Ontera
  • OpGen
  • OPKO Health
  • Orangelife Comercio e Industria
  • Oranoxis
  • OraSure Technologies
  • Orchid Biomedical Systems
  • Oscar Medicare
  • Owen Mumford
  • Owlstone Medical
  • Pacific Image Electronics
  • PAI Life Sciences
  • PATH
  • PhageTech
  • Pinakin Pharmaceuticals
  • PointCare Technologies
  • Prechek Bio
  • Precision Biosensor
  • Predictive Laboratories
  • Premier Medical
  • PRIMA Lab
  • Pro Med Diagnostics
  • Proactive Diagnostics
  • Prominex
  • ProteinLogic
  • QIAGEN
  • Qualpro Diagnostics
  • QuantaSpec
  • QuantuMDx
  • Quaphaco
  • Quartzy
  • Quibasa-Bioclin
  • Quidel
  • Quimica Valaner
  • Radiometer Medical India
  • Randox Testing Services
  • Rapid Biosensor Systems
  • Rapid Diagnostics Group
  • Rapid Diagnostics ML
  • RapiGEN
  • RayBiotech
  • R-Biopharm
  • REAGEN
  • Relay Medical
  • Response Biomedical
  • Reszon Diagnostics International
  • Rheonix
  • Righton
  • RINGBIO
  • Roche
  • ROI Scientific
  • RPS Diagnostics
  • Rutgers University
  • SA Scientific
  • Sagentia
  • Savyon Diagnostics
  • Scanogen
  • SD BIOSENSOR
  • SEASUN BIOMATERIALS
  • Sedia Biosciences
  • Sekisui Chemical
  • Sekisui Diagnostics
  • Seloi Healthcare
  • SensDx
  • Sense Biodetection
  • Sepsitron
  • Shanghai Chemtron Biotech
  • Shanghai Kehua Bio-Engineering
  • Shenzhen Bioeasy Biotechnology
  • Sherlock Biosciences
  • Sight Diagnostics
  • SkillCell
  • Skolkovo Institute of Science and Technology
  • Span Biotech
  • Spartan Bioscience
  • SpeeDx
  • Spindiag
  • SSI Diagnostica
  • Stony Brook Medicine
  • Sugentech
  • Sure Bio-Tech
  • SureScreen Diagnostics
  • Swift Molecular Diagnostics
  • Sysmex Partec
  • Talis Biomedical
  • Tangen Biosciences
  • Tata Trusts
  • TAUNS Laboratories
  • Technogenetics
  • Teco Diagnostics
  • The eNose Company
  • The Inovie Group
  • Theranostica
  • Thermal Gradient
  • Thermo Fisher Scientific
  • TM Testing
  • Topcare Biotech
  • Trinity Biotech
  • TrivTech Dx
  • Tulip Diagnostics
  • Turk Lab
  • UCP Biosciences
  • ulti med Products
  • Unilatex.com
  • Unimed International
  • UNITAID
  • United States Department of Health and Human Services (HHS)
  • University of Oxford
  • University of Tokyo
  • UrSure
  • Ustar Biotechnologies
  • Vazyme Biotech
  • VedaLab
  • Veredus Laboratories
  • Vidant Health
  • VIDIA
  • Viola Diagnostic Systems
  • Vision Biotechnology
  • VivaChek Laboratories
  • VOGO
  • W.H.P.M.
  • Wageningen University & Research
  • WAMA Diagnóstica
  • Webb Diagnostic Technologies
  • Wellgistics
  • WELLS BIO
  • Wezi Medical Center
  • World Hepatitis Alliance
  • Wuhan UNscience Biotechnology
  • XCR Diagnostics
  • Xiamen Biotime Biotechnology
  • Xiamen Boson Biotech
  • Xinhua Healthcare Industry
  • Yaathum Biotech
  • Zephyr Biomedicals
  • Zhuhai Livzon Diagnostics
  • ZymeTx
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll